MentionFox
Home › funding signals › Osmind
Accelerator · announced

Osmind (YC S20) — Platform for breakthrough mental health research and treatment

Osmind appears in Y Combinator's company directory in the Summer 2020 batch, listed 2020-08-23. Platform for breakthrough mental health research and treatment.

Just raised? Share it.

Osmind: Accepted into Y Combinator Summer 2020

What do you want to do with Osmind?

Osmind

New accelerator entry · 2020-08-23 · the record

Summer 2020
batch
55
people
Early
stage
United States of America
region
Open the record →

In their words

Osmind is the premier platform for clinicians and researchers advancing new life-saving mental health treatments. Today, mental health disorders are one of the leading causes of death worldwide, especially among young adults, and are tied to shortening lifespans. While there have been developments in new psychiatric medications since the first FDA approval in 1954, today there is a growing movement among clinicians, patients, and researchers who are recognizing the need to accelerate new science. The Osmind treatment platform is the first and only solution that solves specific challenges faced by neuropsychiatric clinics, spanning general psychiatry and interventional psychiatry (transcranial magnetic stimulation, ketamine, SPRAVATO®, psychedelic medicine, electroconvulsive therapy). The core electronic health record (EHR) technology is precisely developed for interventional treatment workflows and designed to support a strong therapeutic alliance, including journaling tools and assistance with health plan reimbursement, which is a significant access hurdle for millions of patients. Research from our platform is already helping to set new standards for mental health interventions. For example, in the largest published real-world analysis of ketamine infusion therapy for depression, we teamed up with Stanford University School of Medicine to share findings in the Journal of Affective Disorders (March 2022). We have multiple ongoing research studies leveraging our proprietary real-world data, including an even larger ketamine analysis leveraging machine learning to predict treatment outcomes. Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists. We are backed by top investors including DFJ Growth, General Catalyst, Future Ventures, Tiger Global, and Y Combinator.

What the record says

BatchSummer 2020
Announced2020-08-23
StageEarly
StatusActive
Team size55
IndustryHealthcare
Sub-industryHealthcare -> Healthcare IT
SectorsMental Health Tech, SaaS, Health Tech
RegionsUnited States of America, America / Canada, Remote, Partly Remote
BasedSan Francisco, CA, USA
HiringNo
Sitehttps://osmind.org/

The full profile

Checking your access…

Is this you?

If you're behind Osmind: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. FoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.

Sourced from the company's Y Combinator directory entry.

Tools for this story

Each opens in a new tab, filled in for Osmind. With no account yet, you sign up free and land on the result.

Cite this page

Permanent URL: https://mentionfox.com/funding/yc-osmind
Last updated 2026-09-26
Primary record: Y Combinator directory entry
Osmind (YC S20) — Platform for breakthrough mental health research and treatment. MentionFox, 2026-09-26. https://mentionfox.com/funding/yc-osmind